---
document_datetime: 2025-09-17 11:21:59
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zirabev-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: zirabev-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.6339748
conversion_datetime: 2025-12-22 07:27:45.649279
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zirabev

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber    | Scope                               | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|-------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | B.II.b.2.cReplacementor additionofa | 11/09/2025                          |                                          | Annex II and                    |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000278463                     | manufacturerresponsibleforimportation and/or batch release - B.1I.b.2.c.1 Not includingbatchcontrol/testing-Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            | PL                     |                                                                                                                                                                                                                                                                                          |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000282597 | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS-C.I.z Other variation-Accepted C.I.z - Type IB - To update Sections 2, 4.4, 5.1 and 6.1 of the SmPC and Sections 2 and 6 of thePL with information on the excipient polysorbate 80, based on the Annex to the EuropeanCommissionguideline on 'Excipients in the labelling and package leafletofmedicinal productsforhumanuse'.                                                                                                                                                                                                                                                                       | 18/07/2025 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                          |
| Variation type IB / EMA/VR/0000273197 | C.I.2 Change(s) in the Summary of Product Characteristics,LabellingorPackageLeaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH-Accepted C.I.2.a-ToupdatethePIwitheditorial changestoalignwiththePIofthereference product. The changes are updates to wording (e.g., spelling, grammar, use of capitalization/hyphenation,minor rewording) and formatting of numbers, ranges, units of measureandstoragetemperatures throughouttheSmPCandPL.Theupdates | 10/06/2025 | SmPC and PL            | To update the PI with editorial changes to align with the PI of the reference product.The changes follow assessmentof thesamechanges to thereference product Avastin. In addition, the MAH took the opportunity to update the information for the local representative for IE in the PL. |

<div style=\"page-break-after: always\"></div>

|                                      | include a correction to the wording of a cross-referencewithinpost-marketingADR Table3insection4.8of theSmPC, relocationof thefootnotesforTables13and 15insection5.1 of theSmPC to thebottom of each table and a minor correction to the wordingof asubheadinginTable19 in section5.1oftheSmPC.The changesfollow assessment of the same changes to the reference product Avastin.In addition, the MAH tooktheopportunitytoupdatethe informationforthelocalrepresentativefor IEinthePL.Furthermore,theMAH took theopportunitytoupdatetotheSmPCand PL toalignwithQRDtemplateversion10.4, includingremoval of'UnitedKingdom (NorthernIreland)'from thelistoflocal representatives in the PL.   |            |     |
|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation typeII / EMA/VR/0000254313 | This was an application for a group of variations. B.II.b.3 Change in the manufacturing process of the finished product, including an intermediateused in themanufacture of the finishedproduct-B.I1.b.3.cTheproductis a biological/immunological medicinalproduct and the change requires an assessment of comparability-Accepted B.II.b.4 Change in the batch size (including batch size ranges) of the finished product -                                                                                                                                                                                                                                                                | 08/05/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | B.I1.b.4.a Up to 10-fold compared to the originally approved batch size - Accepted                                                                                                                                                                                  |            |     |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000256400 | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites)-A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted | 04/03/2025 | N/A |